Stock 2171 CARSGEN THERAPEUTICS HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Market Closed - Hong Kong S.E.
Other stock markets
 09:09:00 03/05/2024 BST 		5-day change 1st Jan Change
6.19 HKD -0.80% Intraday chart for CARsgen Therapeutics Holdings Limited +13.58% -4.77%
04-29 CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations CI
04-12 Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024 MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration
CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting
CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting
Catalyst Pharmaceuticals Names Richard Daly as Chief Executive
CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival
CARsgen Therapeutics Holdings Limited Announces Collaboration Agreement for Zevor-Cel Commercialization in Mainland China with Huadong Medicine
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Moderna, CARsgen Therapeutics Enter Into Cancer Collaboration
CARsgen Therapeutics Holdings Limited Announces Collaboration with Moderna, Inc. to Evaluate CT041 in Combination with an Mrna Cancer Vaccine
CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee
Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee
CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041
CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2171 Stock
  4. News CARsgen Therapeutics Holdings Limited
  5. Other languages